Excessive pricing of medicines is never far from the public eye, particularly in times of pressure on healthcare spending, and all the more so since the furore over Martin Shkreli's decision to raise the US price of Turing Pharmaceuticals AG's toxoplasmosis drug Daraprim by more than 5,000% in 2015.
Shkreli's move was certainly an eye-catching maneuver, and one that most in the pharmaceutical company industry were quick to distance...





